New Study Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions

Last updated: 30th June, 2022

Products are for professional/laboratory use only.

New Study Led by Memorial Sloan Kettering Cancer Center (NY, US)

This study shows that Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods:

  • Therapeutically actionable gene fusions drive approximately 10% of non-small-cell lung cancers1
  • Current molecular methods including Next Generation Sequencing (NGS) are complex with long turnaround times
  • Study2 demonstrates the Idylla™ GeneFusion Assay (RUO3) enables more rapid screening of targetable fusions compared to routine methods

Biocartis announces the publication of a new study in the Journal of Molecular Diagnostics on the Idylla™ GeneFusion Assay (RUO) for rapid detection of targetable fusions involving ALK, ROS1, RET, and NTRK1/2/3 and MET exon 14 skipping mutations.

The study concluded: “The assay enables rapid screening for clinically actionable kinase alterations with quicker turnaround and lower tissue requirements compared to immunohistochemistry and molecular methods, while also circumventing the infrastructure dependencies associated with Next Generation Sequencing (NGS) and fluorescence in situ hybridization”.

Therapeutically actionable gene fusions drive approximately 10% of non-small-cell lung cancers1 (NSCLC). Up to 40% of rearrangement-driven lung cancers are diagnosed at an advanced stage (III to IV)4, however tyrosine kinase inhibitor therapy typically induces rapid and profound clinical improvement5. As such, timely recognition of these alterations is critical in the clinic.

Current methods to detect kinase fusions such as fluorescence in situ hybridization (FISH) or NGS can:

  • Be complex to perform
  • Require a large lab infrastructure
  • Have long turnaround times
  • Be cumbersome when it comes to interpretation of the data

Although NGS has become the mainstay for high throughput therapeutic target search, most NGS assays:

  • Have high tissue requirements
  • Need turnaround times of 2 to 3 weeks
  • Bring about underlying genomic and biologic complexities that can lead to false-negative gene fusion results

The study analyzed 143 independent FFPE6 tumor samples. The study stated that “testing was successful in 142 (99%) cases”. Furthermore, the study stated that “the Idylla™ GeneFusion Assay demonstrated a sensitivity of 97% (28/29), 100% (31/31), 92% (22/24), 81% (22/27), and 100% (20/20) for ALK, RET, ROS1, and NTRK1/2/3 rearrangements and MET exon 14 skipping alterations, respectively, with 100% specificity for all.”

The fully automated Idylla™ GeneFusion Assay (RUO) detects ALK, ROS1, RET, NTRK1/2/3 rearrangements and MET exon 14 skipping in a single cartridge, with less than 2 minutes hands-on time and results available in approx. 180 minutes.

Access the full article

View Here >

Learn more about Idylla™ Gene Fusion Assay (RUO)

View Here >


  1. Lee SE, et al., ‘Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma’, Mod Pathol 2015, 28:468e479; and Pan Y et al., : ‘ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features’, Lung Cancer 2014, 84:121e126
  2.  M. Arcila et al., ‘Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations’, Published 14 April 2022, DOI:
  3. Research Use Only, not for use in diagnostic procedures
  4.  Kim H et al., ‘A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype’, PLoS One 2013, 8:e76999
  5. Kitazawa S, et al., ‘Successful use of extracorporeal membrane oxygenation for airway-obstructing lung adenocarcinoma’, Thorac Cancer 2020, 11:3024e3028
  6. Formalin Fixed, Paraffin Embedded

Request a Quote

Request Quote

Go BackGo Back